Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    ZN-C3

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 393,691Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024
    Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942660/0/en/Zentalis-Pharmaceuticals-to-Present-Preclinical-Azenosertib-Data-at-ESMO-2024.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths
    Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths

    19 Jun 2024

    // BIOSPACE

    https://www.biospace.com/article/zentalis-hit-with-fda-partial-clinical-hold-on-three-cancer-studies-following-two-patient-deaths-/

    BIOSPACE
    19 Jun 2024
    Share Share
    Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress
    Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress

    07 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/07/2876560/0/en/Zentalis-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Operational-Progress.html

    GLOBENEWSWIRE
    07 May 2024
    Share Share
    Zentalis to Highlight Preclinical Data Demonstrating Azenosertib at AACR
    Zentalis to Highlight Preclinical Data Demonstrating Azenosertib at AACR

    02 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/02/2856461/0/en/Zentalis-Pharmaceuticals-to-Highlight-Preclinical-Data-Demonstrating-that-WEE1-Inhibitor-Azenosertib-Exerts-Synergistic-Anti-tumor-Activity-with-KRAS-G12C-Inhibitors-at-AACR-Annual.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    Zentalis Announces Azenosertib Dosing Doubles Efficacy Over Continuous Dosing
    Zentalis Announces Azenosertib Dosing Doubles Efficacy Over Continuous Dosing

    06 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/06/2682584/0/en/Zentalis-Announces-Intermittent-Azenosertib-Monotherapy-Dosing-Nearly-Doubles-Efficacy-Over-Continuous-Dosing.html

    GLOBENEWSWIRE
    06 Jun 2023
    Share Share
    Zentalis Announces Presentation of Phase 1b Data Demonstrating Azenosertib
    Zentalis Announces Presentation of Phase 1b Data Demonstrating Azenosertib

    25 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/25/2676791/0/en/Zentalis-Announces-Presentation-of-Positive-Phase-1b-Data-Demonstrating-Durable-Responses-and-Favorable-Safety-Profile-of-Azenosertib-in-Combination-with-Chemotherapy-at-the-2023-A.html

    GLOBENEWSWIRE
    25 May 2023
    Share Share